Tissue integrity signals communicated by highmolecular weight hyaluronan and the resolution of inflammation

Immunologic Research

Volumn 58, Issue 2-3, 2014, Pages 186-192

  Ruppert, S M ^a   Hawn, T R ^b   Arrigoni, A ^a   Wight, T N ^c   Bollyky, P L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

CD44; DAMP; Danger signals; ECM; Hyaluronan; Integrity signal

Indexed keywords

BIOLOGICAL FACTOR; CD44V ANTIGEN; DANGER ASSOCIATED MOLECULAR PATTERN; HYALURONIC ACID; POLYSACCHARIDE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; HERMES ANTIGEN; PATTERN RECOGNITION RECEPTOR; PROTEIN BINDING;

CATABOLISM; CELL FUNCTION; CROSS LINKING; EXTRACELLULAR MATRIX; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; LEUKOCYTE; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; MOLECULAR WEIGHT; NONHUMAN; PATTERN RECOGNITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TISSUE REPAIR; ANIMAL; CHEMISTRY; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIGENS, CD44; EXTRACELLULAR MATRIX; HUMANS; HYALURONIC ACID; INFLAMMATION; MOLECULAR WEIGHT; PROTEIN BINDING; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION;

EID: 84901626643     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-014-8495-2     Document Type: Review

References (78)

1. Termeer C, et al. Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med. 2002;195:99-111. (Pubitemid 34074500)
2. Laurent TC, et al. The structure and function of hyaluronan: an overview. Immunol Cell Biol. 1996;74:A1-7. (Pubitemid 26174722)
3. Jiang D, et al. Hyaluronan as an immune regulator in human diseases. Physiol Rev. 2011;91:221-64.
4. Jiang D, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med. 2005;11:1173-9. (Pubitemid 43093664)
5. Itano N, Kimata K. Mammalian hyaluronan synthases. IUBMB Life. 2002;54:195-9. (Pubitemid 36008328)
6. Teder P. Resolution of lung inflammation by CD44. Science. 2002;296:155-8. (Pubitemid 34280077)
7. Delmage JM, et al. The selective suppression of immunogenicity by hyaluronic acid. Ann Clin Lab Sci. 1986;16:303-10. (Pubitemid 16099602)
8. Stern R, Jedrzejas MJ. Hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev. 2006;106:818-39.
9. Neumann A, et al. High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappaB activation and cytokine expression. FEBS Lett. 1999;453:283-7. (Pubitemid 29326664)
10. Stern R, et al. Hyaluronan fragments: an information-rich system. Eur J Cell Biol. 2006;85:699-715. (Pubitemid 44070579)
11. Forrester JV, Balazs EA. Inhibition of phagocytosis by high molecular weight hyaluronate. Immunology. 1980;40:435-46. (Pubitemid 10086557)
12. Suresh R, Mosser DM. Pattern recognition receptors in innate immunity, host defense, and immunopathology. Adv Physiol Educ. 2013;37:284-91.
13. Tian X, et al. High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature. 2013;. doi:10. 1038/nature12234.
14. Tsan M-F, Gao B. Heat shock proteins and immune system. J Leukoc Biol. 2009;85:905-10.
15. Gasse P, et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med. 2009;179:903-13.
16. Campo GM, et al. Hyaluronan reduces inflammation in experimental arthritis by modulating TLR-2 and TLR-4 cartilage expression. Biochim Biophys Acta. 2011;1812:1170-81.
17. Morwood SR, Nicholson LB. Modulation of the immune response by extracellular matrix proteins. Arch Immunol Ther Exp. 2006;54:367-74. (Pubitemid 44968889)
18. Galeano M, et al. Systemic administration of high-molecular weight hyaluronan stimulates wound healing in genetically diabetic mice. Biochim Biophys Acta. 2011;1812:752-9.
19. Powell JD, Horton MR. Threat matrix: low-molecular-weight hyaluronan (HA) as a danger signal. Immunol Res. 2005;31:207-18. (Pubitemid 40628958)
20. Hašová M, et al. Hyaluronan minimizes effects of UV irradiation on human keratinocytes. Arch Dermatol Res. 2011;303:277-84.
21. Tesar BM, et al. The role of hyaluronan degradation products as innate alloimmune agonists. Am J Transpl. 2006;6:2622-35. (Pubitemid 44571682)
22. Huang PM, et al. High MW hyaluronan inhibits smoke inhala-tion- induced lung injury and improves survival. Respirology. 2010;15:1131-9.
23. Ye J, et al. High molecular weight hyaluronan decreases oxidative DNA damage induced by EDTA in human corneal epithelial cells. Eye (Lond). 2012;26:1012-20.
24. Austin JW, et al. High molecular weight hyaluronan reduces lipopolysaccharide mediated microglial activation. J Neurochem. 2012;122:344-55.
25. Ponta H, et al. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4:33-45. (Pubitemid 36077255)
26. Yamawaki H, et al. Hyaluronan receptors involved in cytokine induction in monocytes. Glycobiology. 2008;19:83-92.
27. De la Motte C, et al. Platelet-derived hyaluronidase 2 cleaves hyaluronan into fragments that trigger monocyte-mediated production of proinflammatory cytokines. Am J Pathol. 2009;174:2254-64.
28. Campo GM, et al. Small hyaluronan oligosaccharides induce inflammation by engaging both toll-like-4 and CD44 receptors in human chondrocytes. Biochem Pharmacol. 2010;80:480-90.
29. van der Windt GJW, et al. The role of CD44 in the acute and resolution phase of the host response during pneumococcal pneumonia. Lab Invest. 2011;91:588-97.
30. McKee CM, et al. Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest. 1996;98:2403-13. (Pubitemid 26394217)
31. Horton MR, et al. Regulation of hyaluronan-induced chemokine gene expression by IL-10 and IFN-gamma in mouse macrophages. J Immunol. 1998;160:3023-30. (Pubitemid 28136759)
32. Huebener P, et al. CD44 is critically involved in infarct healing by regulating the inflammatory and fibrotic response. J Immunol. 2008;180:2625-33.
33. Scheibner KA, et al. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol. 2006;177:1272-81. (Pubitemid 44036633)
34. Zheng L, et al. Regulation of colonic epithelial repair in mice by toll-like receptors and hyaluronic acid. YGAST. 2009;137:2041-51.
35. Baaten BJG, et al. CD44 regulates survival and memory development in Th1 cells. Immunity. 2010;32:104-15.
36. Bollyky PL, et al. ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors. Proc Natl Acad Sci USA. 2011;108:7938-43.
37. Cuff CA, et al. The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J Clin Invest. 2001;108:1031-40. (Pubitemid 32946077)
38. Naor D, et al. CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice. Ann NY Acad Sci. 2007;1110:233-47. (Pubitemid 350043012)
39. Taylor KR, et al. Recognition of hyaluronan released in sterile injury involves a unique receptor complex dependent on Toll-like receptor 4, CD44, and MD-2. J Biol Chem. 2007;282:18265-75. (Pubitemid 47100227)
40. Muto J, et al. Engagement of CD44 by hyaluronan suppresses TLR4 signaling and the septic response to LPS. Mol Immunol. 2009;47:449-56.
41. Asari A, et al. Oral administration of high molecular weight hyaluronan (900 kDa) controls immune system via Toll-like receptor 4 in the intestinal epithelium. J Biol Chem. 2010;285:24751-8.
42. Yasuda T. Hyaluronan inhibits Akt, leading to nuclear factor-κB down-regulation in lipopolysaccharide-stimulated U937 macrophages. J Pharmacol Sci. 2011;115:509-15.
43. Liang J, et al. CD44 is a negative regulator of acute pulmonary inflammation and lipopolysaccharide-TLR signaling in mouse macrophages. J Immunol. 2007;178:2469-75. (Pubitemid 46233447)
44. Kawana H, et al. CD44 suppresses TLR-mediated inflammation. J Immunol. 2008;180:4235-45.
45. Sakaguchi S, et al. FOXP3 + regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10:490-500.
46. Wildin RS, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001;27:18-20. (Pubitemid 32044512)
47. Huter EN, et al. TGF-β-induced Foxp3 +regulatory T cells rescue scurfy mice. Eur J Immunol. 2008;38:1814-21.
48. Tang Q, et al. CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol. 2012;4:11-21.
49. Firan M, et al. Suppressor activity and potency among regulatory T cells is discriminated by functionally active CD44. Blood. 2006;107:619-27. (Pubitemid 43076386)
50. Bollyky PL, et al. Cutting edge: high molecular weight hyaluronan promotes the suppressive effects of CD4 + CD25 + regulatory T cells. J Immunol. 2007;179:744-7.
51. Bollyky PL, et al. Intact extracellular matrix and the maintenance of immune tolerance: high molecular weight hyaluronan promotes persistence of induced CD4 + CD25 + regulatory T cells. J Leukoc Biol. 2009;86:567-72.
52. Bollyky PL, et al. CD44 costimulation promotes FoxP3 + regulatory T cell persistence and function via production of IL-2, IL- 10, and TGF-beta. J Immunol. 2009;183:2232-41.
53. Larkin J, et al. CD44 differentially activates mouse NK T cells and conventional T cells. J Immunol. 2006;177:268-79. (Pubitemid 43939138)
54. Föger N, et al. CD44 supports T cell proliferation and apoptosis by apposition of protein kinases. Eur J Immunol. 2000;30:2888-99.
55. Bollyky PL, et al. Th1 cytokines promote T-cell binding to antigen-presenting cells via enhanced hyaluronan production and accumulation at the immune synapse. Cell Mol Immunol. 2010;7:211-20.
56. Hegde VL, et al. CD44 mobilization in allogeneic dendritic cell-T cell immunological synapse plays a key role in T cell activation. J Leukoc Biol. 2008;84:134-42. (Pubitemid 351960288)
57. Banerji S, et al. Structures of the Cd44-hyaluronan complex provide insight into a fundamental carbohydrate-protein interaction. Nat Struct Mol Biol. 2007;14:234-9. (Pubitemid 46355571)
58. King A, et al. Interleukin-10 regulates the fetal hyaluronan-rich extracellular matrix via a STAT3-dependent mechanism. J Surg Res. 2013;184:671-7.
59. Mizrahy S, et al. Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. J Control Release. 2011;156:231-8.
60. Wolny PM, et al. Analysis of CD44-hyaluronan interactions in an artificial membrane system: insights into the distinct binding properties of high and low molecular weight hyaluronan. J Biol Chem. 2010;285:30170-80.
61. Fujii Y, et al. Crosslinking of CD44 on human osteoblastic cells upregulates ICAM-1 and VCAM-1. FEBS Lett. 2003;539:45-50. (Pubitemid 36351285)
62. Hutás G, et al. CD44-specific antibody treatment and CD44 deficiency exert distinct effects on leukocyte recruitment in experimental arthritis. Blood. 2008;112:4999-5006.
63. Marhaba R, et al. CD44v6 promotes proliferation by persisting activation of MAP kinases. Cell Signal. 2005;17:961-73. (Pubitemid 40719117)
64. Sugahara KN, et al. Hyaluronan oligosaccharides induce CD44 cleavage and promote cell migration in CD44-expressing tumor cells. J Biol Chem. 2003;278:32259-65. (Pubitemid 37048419)
65. Harada H, Takahashi M. CD44-dependent intracellular and extracellular catabolism of hyaluronic acid by hyaluronidase-1 and -2. J Biol Chem. 2007;282:5597-607. (Pubitemid 47093756)
66. Bourguignon LYW, et al. CD44 interaction with Na + -H + exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem. 2004;279:26991-7007. (Pubitemid 38812535)
67. Day AJ, Prestwich GD. Hyaluronan-binding proteins: tying up the giant. J Biol Chem. 2002;277:4585-8. (Pubitemid 34968483)
68. Day AJ, De la Motte CA. Hyaluronan cross-linking: a protective mechanism in inflammation? Trends Immunol. 2005;26:637-43. (Pubitemid 41628196)
69. Baranova NS, et al. The inflammation-associated protein TSG-6 cross-links hyaluronan via hyaluronan-induced TSG-6 oligomers. J Biol Chem. 2011;286:25675-86.
70. Zhuo L, et al. SHAP potentiates the CD44-mediated leukocyte adhesion to the hyaluronan substratum. J Biol Chem. 2006;281:20303-14. (Pubitemid 44065805)
71. Lesley J, et al. TSG-6 modulates the interaction between hyaluronan and cell surface CD44. J Biol Chem. 2004;279:25745-54. (Pubitemid 38756838)
72. Tan KT, et al. Characterization of hyaluronan and TSG-6 in skin scarring: differential distribution in keloid scars, normal scars and unscarred skin. J Eur Acad Dermatol Venereol. 2011;25:317-27.
73. Kvezereli M, et al. TSG-6 protein expression in the pancreatic islets of NOD mice. J Mol Histol. 2008;39:585-93.
74. Bárdos T, et al. Anti-inflammatory and chondroprotective effect of TSG-6 (tumor necrosis factor-alpha-stimulated gene-6) in murine models of experimental arthritis. Am J Pathol. 2001;159:1711-21. (Pubitemid 33062514)
75. Kota DJ, et al. TSG-6 produced by hMSCs delays the onset of autoimmune diabetes by suppressing Th1 development and enhancing tolerogenicity. Diabetes. 2013;62:2048-58.
76. Evanko SP, et al. Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration. Matrix Biol. 2012;31:90-100.
77. Liu Y, et al. High-molecular-weight hyaluronan-a possible new treatment for sepsis-induced lung injury: a preclinical study in mechanically ventilated rats. Crit Care. 2008;12:R102.
78. Voigt J, Driver VR. Hyaluronic acid derivatives and their healing effect on burns, epithelial surgical wounds, and chronic wounds: a systematic review and meta-analysis of randomized controlled trials. Wound Repair Regen. 2012;20:317-31.